The third-quarter results for Pfizer Inc. ( NYSE:PFE ) were released last week, making it a good time to revisit ...

Pfizer stock dipped early Tuesday despite hiking its 2025 profit guidance, as third-quarter sales and earnings both toppled ...

Pfizer’s pricing deal with the Trump administration, which won the company a three-year exemption from sector-specific ...

Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.

Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales ...

NYSE:PFE Earnings and Revenue History November 11th 2025 How Do Unusual Items Influence Profit? To properly understand Pfizer ...

Market Catalysts host Julie Hyman takes a closer look at some of the trending tickers during Tuesday's trading session.

Obesity is a growing problem that now has effective treatments. Pfizer has been eager to develop a strong position in this area. This acquisition gives Pfizer a viable obesity drug candidate. Pfizer's ...